Zacks Investment Research on MSN8d
Inhibikase Therapeutics (IKT) May Find a Bottom Soon, Here's Why You Should Buy the Stock NowA downtrend has been apparent in Inhibikase Therapeutics, Inc. (IKT) lately. While the stock has lost 15.4% over the past two ...
Inhibikase Therapeutics, Inc.’s IKT share price has surged by 18.46%, which has investors questioning if this is right time to sell.
Mr. Iwicki Brings Track Record of Operational Excellence and Significant Expertise in PAH and Cardiovascular Diseases -- -- Amit Munshi Appointed Chair of the Board of Directors -- BOSTON, Feb. 18, ...
Chris Cabell, MD MHS FACC Appointed President and Head of Research & Development --- --- John Adams, PhD Appointed Chief Scientific Officer --- --- Vince Aurentz to join Inhibikase Board of Directors ...
A downtrend has been apparent in Inhibikase Therapeutics, Inc. (IKT) lately. While the stock has lost 15.4% over the past two weeks, it could witness a trend reversal as a hammer chart pattern was ...
BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), today announced the appointment of two ...
BOSTON, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), today announced the appointment of Mark Iwicki as the Company's Chief ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback